Balance Sheet
Accounts PayablesAccumulated ExpensesAssetsCash & EquivalentsCommon EquityCurrent AssetsLiabilities and Shareholders EquityLong-Term Deferred TaxLong-Term InvestmentsNon-Current AssetsNon-Current DebtOperating LeasesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPrepaid AssetsProperty, Plant & Equipment (Net)Retained EarningsShareholder's EquityTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

Centessa Pharmaceuticals (CNTA) Accounts Payables (2022 - 2025)

Centessa Pharmaceuticals (CNTA) has disclosed Accounts Payables for 4 consecutive years, with $8.7 million as the latest value for Q3 2025.

  • On a quarterly basis, Accounts Payables rose 16.66% to $8.7 million in Q3 2025 year-over-year; TTM through Sep 2025 was $8.7 million, a 16.66% increase, with the full-year FY2024 number at $7.1 million, down 39.54% from a year prior.
  • Accounts Payables was $8.7 million for Q3 2025 at Centessa Pharmaceuticals, up from $5.7 million in the prior quarter.
  • In the past five years, Accounts Payables ranged from a high of $14.4 million in Q1 2023 to a low of $5.1 million in Q1 2025.
  • A 4-year average of $9.0 million and a median of $8.2 million in 2022 define the central range for Accounts Payables.
  • Peak YoY movement for Accounts Payables: surged 114.8% in 2023, then tumbled 52.01% in 2024.
  • Centessa Pharmaceuticals' Accounts Payables stood at $13.8 million in 2022, then fell by 14.61% to $11.8 million in 2023, then crashed by 39.54% to $7.1 million in 2024, then increased by 21.56% to $8.7 million in 2025.
  • Per Business Quant, the three most recent readings for CNTA's Accounts Payables are $8.7 million (Q3 2025), $5.7 million (Q2 2025), and $5.1 million (Q1 2025).